» Articles » PMID: 32198650

Comparative Genomic Profiling of Glandular Bladder Tumours

Abstract

Primary glandular bladder tumours (bladder adenocarcinoma [BAC], urachal adenocarcinoma [UAC], urothelial carcinoma with glandular differentiation [UCg]) are rare malignancies with histological resemblance to colorectal adenocarcinoma (CORAD) in the majority of this subgroup. Definite case numbers are very low, molecular data are limited and the pathogenesis remains poorly understood. Therefore, this study was designed to complement current knowledge by in depth analysis of BAC (n = 12), UAC (n = 13), UCg (n = 11) and non-invasive glandular lesions (n = 19). In BAC, in addition to known alterations in TP53, Wnt, MAP kinase and MTOR pathway, mutations in SMAD4, ARID1A and BRAF were identified. Compared to published data on muscle invasive bladder cancer (BLCA) and CORAD, UCg exhibited frequent "urothelial" like alterations while BAC and UAC were characterised by a more "colorectal" like mutational pattern. Immunohistochemically, there was no evidence of DNA mismatch repair deficiency or PD-L1 tumour cell positivity in any sample. Depending on the used antibody 0-45% of BAC, 0-30% of UCg and 0% UAC cases exhibited PD-L1 expressing tumour associated immune cells. A single BAC (9%, 1/11) showed evidence of ARID1A protein loss, and two cases of UCg (20%, 2/10) showed loss of SMARCA1 and PBRM1, respectively. Taken together, our data suggest at least in part involvement of similar pathways driving tumourigenesis of adenocarcinomas like BAC, UAC and CORAD independent of their tissue origin. Alterations of TERT and FBXW7 in single cases of intestinal metaplasia further point towards a possible precancerous character in line with previous reports.

Citing Articles

[Rare tumors and tumor types of the urinary system in the 5th edition of the WHO classification 2022].

Reis H, Al-Ahmadie H, Szarvas T, Grunwald V, Kollermann J, Koll F Pathologie (Heidelb). 2024; 45(6):381-388.

PMID: 38639771 DOI: 10.1007/s00292-024-01329-2.


Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma.

Zheng Y, Peng H, Hu X, Ou Y, Wang D, Wang H Front Pharmacol. 2023; 14:1199395.

PMID: 37324454 PMC: 10267743. DOI: 10.3389/fphar.2023.1199395.


Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

Varadi M, Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O Cancer Med. 2023; 12(7):9041-9054.

PMID: 36670542 PMC: 10134276. DOI: 10.1002/cam4.5639.


A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas.

Dai L, Mugaanyi J, Zhang T, Tong J, Cai X, Lu C PLoS One. 2022; 17(9):e0274823.

PMID: 36126083 PMC: 9488775. DOI: 10.1371/journal.pone.0274823.


Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype.

Almassi N, Whiting K, Toubaji A, Lenis A, Jordan E, Won H JCO Precis Oncol. 2022; 6:e2100392.

PMID: 35731998 PMC: 9249273. DOI: 10.1200/PO.21.00392.


References
1.
Lee S, Lee J, Sim S, Lee Y, Moon K, Lee C . Comprehensive somatic genome alterations of urachal carcinoma. J Med Genet. 2017; 54(8):572-578. DOI: 10.1136/jmedgenet-2016-104390. View

2.
Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth L . Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. Urol Oncol. 2014; 33(1):21.e1-21.e9. DOI: 10.1016/j.urolonc.2014.10.013. View

3.
Hurst C, Platt F, Knowles M . Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol. 2013; 65(2):367-9. DOI: 10.1016/j.eururo.2013.08.057. View

4.
Lee Y, Moon K, Jeong C, Kwak C, Kim H, Ku J . Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS One. 2014; 9(9):e107027. PMC: 4156382. DOI: 10.1371/journal.pone.0107027. View

5.
Tolcher A, Peng W, Calvo E . Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. Mol Cancer Ther. 2018; 17(1):3-16. DOI: 10.1158/1535-7163.MCT-17-0349. View